Sermorelin vs Tesamorelin

Sermorelin is human GHRH(1-29) amide. Tesamorelin is a stabilized analogue of the 44-amino-acid hormone with an N-terminal trans-3-hexenoyl group. The fragment length and modification distinguish their chemical identities.

Both descriptions refer to the GHRH receptor and cyclic AMP signaling, but the shared pathway does not establish identical degradation or exposure. The formula and molecular weight belong to each declared entity and should not be transferred between them.

Sermorelin: Sermorelin is the amidated 1-29 fragment of human growth hormone-releasing hormone. In research models, it binds to the GHRH receptor and acts as an agonist of that pathway in the anterior pituitary. It has been investigated in models of somatotropic axis signaling in rodent studies.

Tesamorelin: Tesamorelin is a stabilized analog of the 44-amino-acid human growth hormone-releasing hormone, modified with a trans-3-hexenoyl group at the N-terminus. In research models, it binds to the GHRH receptor in the anterior pituitary and acts on that signaling pathway. It has been studied in models of the somatotropic axis and adipose tissue distribution in preclinical research.

Sermorelin: The 1-29 fragment retains the minimal region described for binding to the GHRH receptor. Receptor activation increases cyclic AMP in cellular models.

Tesamorelin: The GHRH receptor is a Gs protein-coupled receptor whose activation increases intracellular cyclic AMP in cellular models. The N-terminal modification reduces enzymatic degradation in in vitro studies.

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.